PortalPublikationenCirculating free DNA integrity and concentration as independ...

Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer

Standard

Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer. / Cheng, Jie; Holland-Letz, Tim; Wallwiener, Markus; Surowy, Harald; Cuk, Katarina; Schott, Sarah; Trumpp, Andreas; Pantel, Klaus; Sohn, Christof; Schneeweiss, Andreas; Burwinkel, Barbara.

in: BREAST CANCER RES TR, Jahrgang 169, Nr. 1, 05.2018, S. 69-82.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Cheng, J, Holland-Letz, T, Wallwiener, M, Surowy, H, Cuk, K, Schott, S, Trumpp, A, Pantel, K, Sohn, C, Schneeweiss, A & Burwinkel, B 2018, 'Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer', BREAST CANCER RES TR, Jg. 169, Nr. 1, S. 69-82. https://doi.org/10.1007/s10549-018-4666-5

APA

Cheng, J., Holland-Letz, T., Wallwiener, M., Surowy, H., Cuk, K., Schott, S., Trumpp, A., Pantel, K., Sohn, C., Schneeweiss, A., & Burwinkel, B. (2018). Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer. BREAST CANCER RES TR, 169(1), 69-82. https://doi.org/10.1007/s10549-018-4666-5

Vancouver

Cheng J, Holland-Letz T, Wallwiener M, Surowy H, Cuk K, Schott S et al. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer. BREAST CANCER RES TR. 2018 Mai;169(1):69-82. https://doi.org/10.1007/s10549-018-4666-5

Bibtex

@article{9704ab19787d47aaa693f82288b2e21f,
title = "Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer",
abstract = "PURPOSE: Non-invasive blood-based molecular markers have been investigated for cancer diagnosis and prognosis. Circulating free or cell-free DNA (cfDNA) variables have been shown to be putative markers in breast cancer prognosis.METHODS: Here, we investigated the potential prognostic ability of cfDNA concentration and cfDNA integrity (cfDI) in a study cohort of 268 patients by quantitative PCR. We compared cfDNA concentration and cfDI at baseline and after one cycle of therapy in metastatic breast cancer (MBC) patients.RESULTS: A significantly increased cfDI (P = 1.21E-7 for ALU and P = 1.87E-3 for LINE1) and decreased cfDNA concentration (P = 1.17E-3 for ALU and P = 1.60E-2 for LINE1) in both repetitive DNA elements after one cycle of therapy was observed. A multiple Cox regression model indicated that cfDI and cfDNA concentration can serve as independent prognostic markers in patients at baseline with HR (95% CI) of 0.70 (0.48-1.01) for ALU cfDI, 0.63 (0.44-0.92) for LINE1 cfDI, 2.44 (1.68-3.53) for ALU cfDNA concentration, and 2.12 (1.47-3.06) for LINE1 cfDNA concentration and after one cycle of therapy with HR (95% CI) of 0.59 (0.42-0.84) for ALU cfDI, 0.51 (0.36-0.74) for LINE1 cfDI, 1.59 (1.31-1.92) for ALU cfDNA concentration, and 1.30 (1.17-1.45) for LINE1 cfDNA concentration, respectively. By comparing integrated prediction error of different models, cfDNA variables were shown to improve the prognostic power of the CTC status.CONCLUSIONS: We hereby show that cfDNA variables, especially in combination with other markers, can serve as attractive prognostic markers for MBC patients at baseline and during the systematic therapy.",
keywords = "Journal Article",
author = "Jie Cheng and Tim Holland-Letz and Markus Wallwiener and Harald Surowy and Katarina Cuk and Sarah Schott and Andreas Trumpp and Klaus Pantel and Christof Sohn and Andreas Schneeweiss and Barbara Burwinkel",
year = "2018",
month = may,
doi = "10.1007/s10549-018-4666-5",
language = "English",
volume = "169",
pages = "69--82",
journal = "BREAST CANCER RES TR",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

RIS

TY - JOUR

T1 - Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer

AU - Cheng, Jie

AU - Holland-Letz, Tim

AU - Wallwiener, Markus

AU - Surowy, Harald

AU - Cuk, Katarina

AU - Schott, Sarah

AU - Trumpp, Andreas

AU - Pantel, Klaus

AU - Sohn, Christof

AU - Schneeweiss, Andreas

AU - Burwinkel, Barbara

PY - 2018/5

Y1 - 2018/5

N2 - PURPOSE: Non-invasive blood-based molecular markers have been investigated for cancer diagnosis and prognosis. Circulating free or cell-free DNA (cfDNA) variables have been shown to be putative markers in breast cancer prognosis.METHODS: Here, we investigated the potential prognostic ability of cfDNA concentration and cfDNA integrity (cfDI) in a study cohort of 268 patients by quantitative PCR. We compared cfDNA concentration and cfDI at baseline and after one cycle of therapy in metastatic breast cancer (MBC) patients.RESULTS: A significantly increased cfDI (P = 1.21E-7 for ALU and P = 1.87E-3 for LINE1) and decreased cfDNA concentration (P = 1.17E-3 for ALU and P = 1.60E-2 for LINE1) in both repetitive DNA elements after one cycle of therapy was observed. A multiple Cox regression model indicated that cfDI and cfDNA concentration can serve as independent prognostic markers in patients at baseline with HR (95% CI) of 0.70 (0.48-1.01) for ALU cfDI, 0.63 (0.44-0.92) for LINE1 cfDI, 2.44 (1.68-3.53) for ALU cfDNA concentration, and 2.12 (1.47-3.06) for LINE1 cfDNA concentration and after one cycle of therapy with HR (95% CI) of 0.59 (0.42-0.84) for ALU cfDI, 0.51 (0.36-0.74) for LINE1 cfDI, 1.59 (1.31-1.92) for ALU cfDNA concentration, and 1.30 (1.17-1.45) for LINE1 cfDNA concentration, respectively. By comparing integrated prediction error of different models, cfDNA variables were shown to improve the prognostic power of the CTC status.CONCLUSIONS: We hereby show that cfDNA variables, especially in combination with other markers, can serve as attractive prognostic markers for MBC patients at baseline and during the systematic therapy.

AB - PURPOSE: Non-invasive blood-based molecular markers have been investigated for cancer diagnosis and prognosis. Circulating free or cell-free DNA (cfDNA) variables have been shown to be putative markers in breast cancer prognosis.METHODS: Here, we investigated the potential prognostic ability of cfDNA concentration and cfDNA integrity (cfDI) in a study cohort of 268 patients by quantitative PCR. We compared cfDNA concentration and cfDI at baseline and after one cycle of therapy in metastatic breast cancer (MBC) patients.RESULTS: A significantly increased cfDI (P = 1.21E-7 for ALU and P = 1.87E-3 for LINE1) and decreased cfDNA concentration (P = 1.17E-3 for ALU and P = 1.60E-2 for LINE1) in both repetitive DNA elements after one cycle of therapy was observed. A multiple Cox regression model indicated that cfDI and cfDNA concentration can serve as independent prognostic markers in patients at baseline with HR (95% CI) of 0.70 (0.48-1.01) for ALU cfDI, 0.63 (0.44-0.92) for LINE1 cfDI, 2.44 (1.68-3.53) for ALU cfDNA concentration, and 2.12 (1.47-3.06) for LINE1 cfDNA concentration and after one cycle of therapy with HR (95% CI) of 0.59 (0.42-0.84) for ALU cfDI, 0.51 (0.36-0.74) for LINE1 cfDI, 1.59 (1.31-1.92) for ALU cfDNA concentration, and 1.30 (1.17-1.45) for LINE1 cfDNA concentration, respectively. By comparing integrated prediction error of different models, cfDNA variables were shown to improve the prognostic power of the CTC status.CONCLUSIONS: We hereby show that cfDNA variables, especially in combination with other markers, can serve as attractive prognostic markers for MBC patients at baseline and during the systematic therapy.

KW - Journal Article

U2 - 10.1007/s10549-018-4666-5

DO - 10.1007/s10549-018-4666-5

M3 - SCORING: Journal article

C2 - 29340881

VL - 169

SP - 69

EP - 82

JO - BREAST CANCER RES TR

JF - BREAST CANCER RES TR

SN - 0167-6806

IS - 1

ER -